AI Engines For more Details: Perplexity Kagi Labs You
Bladder Control: Oxybutynin chloride works by relaxing the bladder muscles, thereby reducing urinary urgency and frequency and decreasing involuntary contractions of the bladder.
Overactive Bladder (OAB): Oxybutynin chloride is commonly prescribed for individuals with OAB, a condition characterized by a sudden and uncontrollable urge to urinate, often resulting in urinary incontinence.
Urinary Incontinence: Oxybutynin chloride may be used to manage urinary incontinence, including urge incontinence (leakage of urine due to sudden urges) and mixed incontinence (combination of urge and stress incontinence).
Side Effects: Oxybutynin chloride can cause various side effects, including dry mouth, constipation, blurred vision, dizziness, drowsiness, and urinary retention. These side effects may occur due to the anticholinergic properties of the medication, which can affect multiple bodily systems.
Cognitive Issues: Oxybutynin chloride, like other anticholinergic medications, has the potential to cause cognitive issues, particularly in older adults. It may impair memory, attention, and concentration and increase the risk of confusion and delirium, especially in individuals with pre-existing cognitive impairment or dementia.
Heat Intolerance: Oxybutynin chloride can reduce sweating, leading to decreased heat dissipation from the body. This may increase the risk of heat-related adverse events, such as heatstroke, especially during hot weather or physical exertion.
Dosage Forms: Oxybutynin chloride is available in various dosage forms, including immediate-release tablets, extended-release tablets, transdermal patches, and topical gel formulations. The choice of formulation depends on individual patient factors and preferences.
Drug Interactions: Oxybutynin chloride may interact with other medications, such as anticholinergic drugs, certain antibiotics, antifungal agents, and medications metabolized by the cytochrome P450 system. It is essential to review the patient's medication list and consider potential interactions before prescribing oxybutynin.
Contraindications: Oxybutynin chloride is contraindicated in individuals with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and hypersensitivity to the medication or its components.
Special Populations: Caution is advised when prescribing oxybutynin chloride to older adults, individuals with cognitive impairment, and those with certain medical conditions, such as liver or kidney impairment, as they may be more susceptible to adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.6 | 0.5 | 0.2 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.5 | 0.12 |
| Allergies | 7.4 | 4.7 | 0.57 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 6.7 | 6.5 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.1 | 0.7 | 3.43 |
| Ankylosing spondylitis | 4.2 | 1.2 | 2.5 |
| Anorexia Nervosa | 1.6 | 2.8 | -0.75 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.3 | 3 |
| Asthma | 4.8 | 2.5 | 0.92 |
| Atherosclerosis | 1.9 | 2.3 | -0.21 |
| Atrial fibrillation | 3.7 | 2.9 | 0.28 |
| Autism | 9.3 | 9.9 | -0.06 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.1 | 0.3 | 2.67 |
| Cancer (General) | 0.9 | 2.6 | -1.89 |
| Carcinoma | 4.6 | 2.6 | 0.77 |
| Celiac Disease | 2.4 | 3.8 | -0.58 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 5 | 7.3 | -0.46 |
| Chronic Kidney Disease | 4.1 | 2.5 | 0.64 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 2 | -0.11 |
| Chronic Urticaria (Hives) | 1.6 | 0.8 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.1 | 2.8 | 1.89 |
| Constipation | 2.1 | 1.3 | 0.62 |
| Coronary artery disease | 2 | 2.6 | -0.3 |
| COVID-19 | 10.6 | 12.2 | -0.15 |
| Crohn's Disease | 8.1 | 5.6 | 0.45 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 11.5 | 8.8 | 0.31 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.6 | 0.06 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 1.9 | 0.63 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 3.4 | 2.3 | 0.48 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4 | 0.43 |
| gallstone disease (gsd) | 3 | 1.2 | 1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 1.1 | 0.55 |
| Generalized anxiety disorder | 2.5 | 2.6 | -0.04 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 0.9 | 1.56 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 3.2 | 1.4 | 1.29 |
| Heart Failure | 4 | 1.9 | 1.11 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.4 | 0.6 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.1 | 6 |
| hyperglycemia | 2 | 1.3 | 0.54 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.4 | 5.3 | -0.2 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 3.1 | 0.7 | 3.43 |
| IgA nephropathy (IgAN) | 1.9 | 4.7 | -1.47 |
| Inflammatory Bowel Disease | 7.4 | 9.5 | -0.28 |
| Insomnia | 2.2 | 2.6 | -0.18 |
| Intelligence | 1.6 | 0.5 | 2.2 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 6.9 | 5.5 | 0.25 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 6.8 | 4.7 | 0.45 |
| Long COVID | 7.2 | 8.7 | -0.21 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.1 | 0.36 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 0.9 | 0.22 |
| ME/CFS with IBS | 1 | 2.2 | -1.2 |
| ME/CFS without IBS | 1 | 2.2 | -1.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.6 | 2.5 |
| Metabolic Syndrome | 7.7 | 7.7 | 0 |
| Mood Disorders | 11.1 | 7.7 | 0.44 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 6.8 | 6 | 0.13 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.8 | 2.8 | -2.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 5 | 0.16 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 10.3 | 7.2 | 0.43 |
| obsessive-compulsive disorder | 6.1 | 3.2 | 0.91 |
| Osteoarthritis | 2.5 | 1.2 | 1.08 |
| Osteoporosis | 2.5 | 1.4 | 0.79 |
| pancreatic cancer | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 7.7 | 6.6 | 0.17 |
| Polycystic ovary syndrome | 6.5 | 3.2 | 1.03 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.8 | 2.3 | 0.22 |
| Psoriasis | 3.2 | 3.1 | 0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8 | 4.3 | 0.86 |
| Rosacea | 0.8 | 1 | -0.25 |
| Schizophrenia | 7.1 | 3.1 | 1.29 |
| scoliosis | 0.5 | 1.2 | -1.4 |
| Sjögren syndrome | 3.1 | 3.2 | -0.03 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.6 | 2.17 |
| Stress / posttraumatic stress disorder | 2.9 | 2.5 | 0.16 |
| Systemic Lupus Erythematosus | 3.9 | 2 | 0.95 |
| Tic Disorder | 1.5 | 1.6 | -0.07 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 5.2 | 4.4 | 0.18 |
| Type 2 Diabetes | 8.6 | 7.9 | 0.09 |
| Ulcerative colitis | 6.1 | 6.7 | -0.1 |
| Unhealthy Ageing | 4.9 | 2.5 | 0.96 |
| Vitiligo | 2.1 | 1.4 | 0.5 |
